PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33048473-11	2020	Pharmacological analysis showed that the administration of two cell cycle inhibitors for inactivating CDC25A phosphatase (NSC95397) and the cyclin E2/cyclin-dependent kinase 2 (CDK2) complex (purvalanol A) increased the dome number independently of MTA.	purvalanol B	192-202	cell division cycle 25A	Homo sapiens	102-108
33048473-11	2020	Pharmacological analysis showed that the administration of two cell cycle inhibitors for inactivating CDC25A phosphatase (NSC95397) and the cyclin E2/cyclin-dependent kinase 2 (CDK2) complex (purvalanol A) increased the dome number independently of MTA.	purvalanol B	192-202	cyclin E2	Homo sapiens	140-175
33048473-11	2020	Pharmacological analysis showed that the administration of two cell cycle inhibitors for inactivating CDC25A phosphatase (NSC95397) and the cyclin E2/cyclin-dependent kinase 2 (CDK2) complex (purvalanol A) increased the dome number independently of MTA.	purvalanol B	192-202	cyclin dependent kinase 2	Homo sapiens	177-181
33116257-9	2020	We identified a combination of ABT-737, a Bcl-2 family inhibitor and Purvalanol A, a CDK inhibitor, as a potential targeted therapy for AML patients with an MLL rearrangement and an FLT3-ITD.	purvalanol B	69-79	lysine methyltransferase 2A	Homo sapiens	157-160
33116257-9	2020	We identified a combination of ABT-737, a Bcl-2 family inhibitor and Purvalanol A, a CDK inhibitor, as a potential targeted therapy for AML patients with an MLL rearrangement and an FLT3-ITD.	purvalanol B	69-79	fms related receptor tyrosine kinase 3	Homo sapiens	182-186
32174040-9	2020	Treatment of T. annulata-infected cells with the CDK1 inhibitor purvalanol A resulted in morphological changes characterized by tubulin-rich cell protrusions and an extension of the schizont, and a dose-dependent reduction of BrdU incorporation and Ki67 staining of T. annulata-infected cells, demonstrating a clear impact on the Theileria-dependent proliferation of the bovine host cell.	purvalanol B	64-74	cyclin dependent kinase 1	Bos taurus	49-53
31330151-6	2019	USP4, another deubiquitinating enzyme with a high sequence homology and domain structure as USP15, also showed purvalanol A-dependent changes in activity and localization.	purvalanol B	111-121	ubiquitin specific peptidase 4	Homo sapiens	0-4
31330151-6	2019	USP4, another deubiquitinating enzyme with a high sequence homology and domain structure as USP15, also showed purvalanol A-dependent changes in activity and localization.	purvalanol B	111-121	ubiquitin specific peptidase 15	Homo sapiens	92-97
31406169-6	2019	To identify factors involved in lysosomal homeostasis, we carried out compound screening and found that the cyclin-dependent kinase (CDK) inhibitors kenpaullone and purvalanol A induce synthesis of cathepsin D and an increase in the number of lysosomes.	purvalanol B	165-175	cathepsin D	Homo sapiens	198-209
30320903-6	2019	Cotreatment of either purvalanol or roscovitine with ERK1/2 inhibitor, U0126, synergistically suppressed cell proliferation, and induced apoptotic action.	purvalanol B	22-32	mitogen-activated protein kinase 3	Homo sapiens	53-59
30320903-5	2019	We reported that purvalanol and roscovitine induced mitochondria membrane potential loss-dependent apoptotic cell death, which was also characterized by activation of several caspases, cleavage of poly (ADP-ribose) polymerase-1 in DU145 and PC3 cells.	purvalanol B	17-27	poly(ADP-ribose) polymerase 1	Homo sapiens	197-227
30320903-5	2019	We reported that purvalanol and roscovitine induced mitochondria membrane potential loss-dependent apoptotic cell death, which was also characterized by activation of several caspases, cleavage of poly (ADP-ribose) polymerase-1 in DU145 and PC3 cells.	purvalanol B	17-27	actin related protein 1B	Homo sapiens	241-244
30320903-8	2019	This study provides biological evidence about purvalanol and roscovitine have apoptotic and antimetastatic effects via MAPK signaling on prostate cancer cell by activation of GSK3beta signaling and inhibition of phosphoinositide-3-kinase/AKT (PI3K/AKT) pathways involved in the EMT process.	purvalanol B	46-56	mitogen-activated protein kinase 3	Homo sapiens	119-123
30320903-8	2019	This study provides biological evidence about purvalanol and roscovitine have apoptotic and antimetastatic effects via MAPK signaling on prostate cancer cell by activation of GSK3beta signaling and inhibition of phosphoinositide-3-kinase/AKT (PI3K/AKT) pathways involved in the EMT process.	purvalanol B	46-56	glycogen synthase kinase 3 beta	Homo sapiens	175-183
30320903-8	2019	This study provides biological evidence about purvalanol and roscovitine have apoptotic and antimetastatic effects via MAPK signaling on prostate cancer cell by activation of GSK3beta signaling and inhibition of phosphoinositide-3-kinase/AKT (PI3K/AKT) pathways involved in the EMT process.	purvalanol B	46-56	AKT serine/threonine kinase 1	Homo sapiens	212-241
30320903-8	2019	This study provides biological evidence about purvalanol and roscovitine have apoptotic and antimetastatic effects via MAPK signaling on prostate cancer cell by activation of GSK3beta signaling and inhibition of phosphoinositide-3-kinase/AKT (PI3K/AKT) pathways involved in the EMT process.	purvalanol B	46-56	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	243-251
30077642-0	2018	Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.	purvalanol B	16-26	aldo-keto reductase family 1 member C3	Homo sapiens	102-125
30077642-0	2018	Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.	purvalanol B	16-26	aldo-keto reductase family 1 member C3	Homo sapiens	127-133
27484210-5	2016	CDK inhibitors in the presence or absence of rapamycin induced cell death via modulating upstream PI3K/AKT/mTOR signaling pathway in LNCaP cells, exclusively only treatment of purvalanol have strong potential to inhibit both upstream and downstream targets of mTOR in LNCaP and DU145 cells.	purvalanol B	176-186	mechanistic target of rapamycin kinase	Homo sapiens	260-264
27484210-7	2016	We confirmed that purvalanol and roscovitine were strong apoptotic and autophagy inducers that based on regulation of PI3K/AKT/mTOR signaling pathway.	purvalanol B	18-28	AKT serine/threonine kinase 1	Homo sapiens	123-126
27484210-7	2016	We confirmed that purvalanol and roscovitine were strong apoptotic and autophagy inducers that based on regulation of PI3K/AKT/mTOR signaling pathway.	purvalanol B	18-28	mechanistic target of rapamycin kinase	Homo sapiens	127-131
27484210-10	2016	In this point, mTOR is a fine-tuning player in purvalanol and roscovitine-induced apoptosis and autophagy via regulation of PI3K/AKT and the downstream targets, which related with cell proliferation.	purvalanol B	47-57	mechanistic target of rapamycin kinase	Homo sapiens	15-19
27484210-10	2016	In this point, mTOR is a fine-tuning player in purvalanol and roscovitine-induced apoptosis and autophagy via regulation of PI3K/AKT and the downstream targets, which related with cell proliferation.	purvalanol B	47-57	AKT serine/threonine kinase 1	Homo sapiens	129-132
25901510-7	2015	HCT 116 colon cancer cells were exposed to purvalanol, which activated ER stress via upregulation of PERK, IRE1alpha gene expression, eIF-2alpha phosphorylation and ATF-6 cleavage at early time-points in the HCT 116 colon cancer cells.	purvalanol B	43-53	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	101-105
25901510-7	2015	HCT 116 colon cancer cells were exposed to purvalanol, which activated ER stress via upregulation of PERK, IRE1alpha gene expression, eIF-2alpha phosphorylation and ATF-6 cleavage at early time-points in the HCT 116 colon cancer cells.	purvalanol B	43-53	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	107-116
25901510-7	2015	HCT 116 colon cancer cells were exposed to purvalanol, which activated ER stress via upregulation of PERK, IRE1alpha gene expression, eIF-2alpha phosphorylation and ATF-6 cleavage at early time-points in the HCT 116 colon cancer cells.	purvalanol B	43-53	eukaryotic translation initiation factor 2A	Homo sapiens	134-144
25901510-7	2015	HCT 116 colon cancer cells were exposed to purvalanol, which activated ER stress via upregulation of PERK, IRE1alpha gene expression, eIF-2alpha phosphorylation and ATF-6 cleavage at early time-points in the HCT 116 colon cancer cells.	purvalanol B	43-53	activating transcription factor 6	Homo sapiens	165-170
25901510-9	2015	Beclin-1 and Atg-5 expression levels were upregulated and LC3 was cleaved after a 6 h purvalanol treatment.	purvalanol B	86-96	beclin 1	Homo sapiens	0-8
25901510-9	2015	Beclin-1 and Atg-5 expression levels were upregulated and LC3 was cleaved after a 6 h purvalanol treatment.	purvalanol B	86-96	autophagy related 5	Homo sapiens	13-18
25901510-9	2015	Beclin-1 and Atg-5 expression levels were upregulated and LC3 was cleaved after a 6 h purvalanol treatment.	purvalanol B	86-96	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	58-61
25901510-10	2015	Purvalanol induced mitochondrial membrane potential loss, caspase-7 and caspase-3 activation and PARP cleavage following a 48 h treatment.	purvalanol B	0-10	caspase 7	Homo sapiens	58-67
25901510-10	2015	Purvalanol induced mitochondrial membrane potential loss, caspase-7 and caspase-3 activation and PARP cleavage following a 48 h treatment.	purvalanol B	0-10	caspase 3	Homo sapiens	72-81
25901510-10	2015	Purvalanol induced mitochondrial membrane potential loss, caspase-7 and caspase-3 activation and PARP cleavage following a 48 h treatment.	purvalanol B	0-10	collagen type XI alpha 2 chain	Homo sapiens	97-101
25088259-0	2014	Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.	purvalanol B	44-54	BCL2 associated X, apoptosis regulator	Homo sapiens	76-79
25088259-4	2014	Exposure of HCT 116 wt and Bax(-/-) cells to roscovitine or purvalanol for 24h decreased cell viability in dose-dependent manner.	purvalanol B	60-70	BCL2 associated X, apoptosis regulator	Homo sapiens	27-30
25088259-5	2014	However, Bax deficient HCT 116 cells were found more resistant against purvalanol treatment compared to wt cells.	purvalanol B	71-81	BCL2 associated X, apoptosis regulator	Homo sapiens	9-12
25088259-8	2014	Inhibition of autophagy by 3-MA treatment enhanced the purvalanol induced apoptotic cell death in HCT 116 Bax(-/-) cells.	purvalanol B	55-65	BCL2 associated X, apoptosis regulator	Homo sapiens	106-109
25036183-9	2014	RESULTS: Pan-CDK inhibitors AT7519, roscovitine and purvalanol A reduced SAMHD1 phosphorylation.	purvalanol B	52-62	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	73-79
24520372-7	2014	Concentration-response confirmation and orthogonal follow-up assays identified two bona fide inducers of Pfn-1, purvalanol and tyrphostin A9, that confirmed in single-cell motility assays and Western blot analyses.	purvalanol B	112-122	profilin 1	Homo sapiens	105-110
23360302-4	2013	Administration of the cdc2 inhibitor purvalanol A restricted compaction of the injury cavity and astrocyte infiltration into the cavity.	purvalanol B	37-47	cyclin dependent kinase 1	Homo sapiens	22-26
22294330-8	2012	We found that roscovitine and purvalanol (each 20 microM) induced apoptosis by activating caspase-9 and -3, and inhibiting the mitochondrial membrane potential in Caco-2 cells.	purvalanol B	30-40	caspase 9	Homo sapiens	90-106
22294330-10	2012	Although both roscovitine and purvalanol induced SSAT expression, they did not exert a significant effect on the APAO expression profile.	purvalanol B	30-40	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	49-53
20825494-7	2010	Furthermore, when compared with PP2, purvalanol A more effectively suppressed the growth of human colon cancer HT29 and SW480 cells, in which Src family kinases and CDKs are activated.	purvalanol B	37-47	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	142-145
20574155-0	2010	VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells.	purvalanol B	34-46	caspase 3	Homo sapiens	56-65
20574155-8	2010	Treatment with 10 muM Purvalanol B failed to either influence proliferation or induce apoptosis.	purvalanol B	22-34	latexin	Homo sapiens	18-21
20596677-8	2010	Indeed, treatment with purvalanol, a cdc2-inhibitor prevents cell cycle arrest, triggering the G2/M transition.	purvalanol B	23-33	cyclin dependent kinase 1	Homo sapiens	37-41
18460467-6	2008	In contrast, pharmacological inhibition of Cdk5 using purvalanol results in only a gradual and incomplete dephosphorylation of CRMP2 at the site targeted by Cdk5 (Ser-522), suggesting a distinct phosphatase targets this residue.	purvalanol B	54-64	cyclin-dependent kinase 5	Mus musculus	43-47
18460467-6	2008	In contrast, pharmacological inhibition of Cdk5 using purvalanol results in only a gradual and incomplete dephosphorylation of CRMP2 at the site targeted by Cdk5 (Ser-522), suggesting a distinct phosphatase targets this residue.	purvalanol B	54-64	dihydropyrimidinase-like 2	Mus musculus	127-132
18460467-6	2008	In contrast, pharmacological inhibition of Cdk5 using purvalanol results in only a gradual and incomplete dephosphorylation of CRMP2 at the site targeted by Cdk5 (Ser-522), suggesting a distinct phosphatase targets this residue.	purvalanol B	54-64	cyclin-dependent kinase 5	Mus musculus	157-161
16733081-5	2006	This effect on RGS2 mRNA was blocked by the cyclin-dependent kinase-2 (cdk2) inhibitors roscovitine and purvalanol.	purvalanol B	104-114	regulator of G protein signaling 2	Homo sapiens	15-19
16733081-5	2006	This effect on RGS2 mRNA was blocked by the cyclin-dependent kinase-2 (cdk2) inhibitors roscovitine and purvalanol.	purvalanol B	104-114	cyclin dependent kinase 2	Homo sapiens	44-69
16733081-5	2006	This effect on RGS2 mRNA was blocked by the cyclin-dependent kinase-2 (cdk2) inhibitors roscovitine and purvalanol.	purvalanol B	104-114	cyclin dependent kinase 2	Homo sapiens	71-75
16611631-4	2006	The Cdk5 and DYRK2 inhibitor purvalanol decreases the phosphorylation of CRMP proteins in neurons, whereas CRMP1 and CRMP2, but not CRMP4, phosphorylation is decreased in Cdk5(-/-) cortices.	purvalanol B	29-39	cyclin dependent kinase 5	Homo sapiens	4-8
16611631-4	2006	The Cdk5 and DYRK2 inhibitor purvalanol decreases the phosphorylation of CRMP proteins in neurons, whereas CRMP1 and CRMP2, but not CRMP4, phosphorylation is decreased in Cdk5(-/-) cortices.	purvalanol B	29-39	dual specificity tyrosine phosphorylation regulated kinase 2	Homo sapiens	13-18
16611631-4	2006	The Cdk5 and DYRK2 inhibitor purvalanol decreases the phosphorylation of CRMP proteins in neurons, whereas CRMP1 and CRMP2, but not CRMP4, phosphorylation is decreased in Cdk5(-/-) cortices.	purvalanol B	29-39	cyclin dependent kinase 5	Homo sapiens	171-175
16140252-13	2005	Using the kinase inhibitors BMS-250595, purvalanol B, AG-12275, flavopiridol, and several other compounds, it is demonstrated that one can obtain excellent comparisons between the Kd values of binding to CDK2 obtained by TdCD and ITC.	purvalanol B	40-52	cyclin dependent kinase 2	Homo sapiens	204-208
15130771-5	2004	Herein we demonstrate that three 2,6,9-trisubstituted purines: olomoucine, roscovitine, and purvalanol, used at concentrations ascribed by others to potently inhibit CDKs 1, 2, and 5, are powerful triggers of death in maturing cerebellar granule neurons, assessed by loss of mitochondrial reductive capacity and differential staining with fluorescent indicators of living/dead neurons.	purvalanol B	92-102	cyclin dependent kinase 1	Homo sapiens	166-170
14671092-7	2004	Cycloheximide block-and-release experiments clearly demonstrated that even in the presence of enough amounts of the BZLF1 protein, purvalanol A blocked expression of lytic viral proteins at transcription level.	purvalanol B	131-141	protein Zta	Human gammaherpesvirus 4	116-121
12226745-0	2002	p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.	purvalanol B	61-71	cyclin dependent kinase 20	Homo sapiens	0-3
12226745-0	2002	p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.	purvalanol B	61-71	interferon induced protein 44	Homo sapiens	4-7
12226745-6	2002	In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction.	purvalanol B	61-71	cyclin dependent kinase 20	Homo sapiens	21-24
12226745-6	2002	In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction.	purvalanol B	61-71	mitogen-activated protein kinase 3	Homo sapiens	25-33
12226745-6	2002	In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction.	purvalanol B	61-71	cyclin dependent kinase 20	Homo sapiens	223-226
12226745-6	2002	In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction.	purvalanol B	61-71	interferon induced protein 44	Homo sapiens	25-28
12226745-6	2002	In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction.	purvalanol B	61-71	mitogen-activated protein kinase 3	Homo sapiens	29-33
12226745-12	2002	When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner.	purvalanol B	29-39	cyclin dependent kinase 20	Homo sapiens	41-44
12226745-12	2002	When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner.	purvalanol B	29-39	interferon induced protein 44	Homo sapiens	45-48
12226745-12	2002	When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner.	purvalanol B	29-39	mitogen-activated protein kinase 3	Homo sapiens	49-53
12226745-12	2002	When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner.	purvalanol B	29-39	cyclin dependent kinase 1	Homo sapiens	58-62
12226745-13	2002	Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases.	purvalanol B	13-23	cyclin dependent kinase 20	Homo sapiens	62-65
12226745-13	2002	Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases.	purvalanol B	13-23	mitogen-activated protein kinase 3	Homo sapiens	66-74
12226745-14	2002	We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs.	purvalanol B	54-64	cyclin dependent kinase 20	Homo sapiens	100-103
12226745-14	2002	We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs.	purvalanol B	54-64	interferon induced protein 44	Homo sapiens	104-107
12226745-14	2002	We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs.	purvalanol B	54-64	mitogen-activated protein kinase 3	Homo sapiens	108-112
12226745-14	2002	We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs.	purvalanol B	54-64	cyclin dependent kinase 1	Homo sapiens	117-121